Navigation Links
Pharma Wholesale and Distribution Market: World Outlook 2012-2022
Date:8/2/2012

NEW YORK, Aug. 2, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Pharma Wholesale and Distribution Market: World Outlook 2012-2022

http://www.reportlinker.com/p0943306/Pharma-Wholesale-and-Distribution-Market-World-Outlook-2012-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pharmaceutical

Report Details Your guide to trends and revenue potential in pharma wholesaling and distribution

Where is the pharmaceutical wholesale and distribution (W&D) industry heading? Visiongain's report shows you potential revenues and trends to 2022, discussing data, opportunities and prospects.

This new study investigates the W&D industry and its market environment. It lets you discover projected revenues at overall world market, main submarket, company and national level to 2022.

You see forecasts of world-level submarkets to 2022, finding potential revenue: • Original-branded drugs• Generic drugs.

How will 11 leading countries perform to 2022? You find W&D revenue forecasts, as well as discussions of what will drive and restrain those national markets:

• US

• Japan

• Germany

• France

• UK

• Spain

• Italy

• China

• Brazil

• Russia

• India.

You also find a revenue forecast to 2022 for the overall European W&D market. Our study lets you assess the worldwide industry and market, seeing trends and outlooks. You find discussions of pharma supply issues such as these:

• Prospects for the pharma distribution chain from 2012 onwards

• Roles of pharmaceutical wholesalers

• Full-line wholesalers (FLWs)

• Short-line wholesalers (SLWs)

• Secondary wholesalers

• Direct-to-pharmacy distribution

• Pharmacy benefit managers

• Generating revenue and profit

• Emerging national markets

• Globalisation and increased demand for medicines.

The report also discusses these activities:• Forward buying• Fee-for-service activities• Serialisation for wholesalers• Specialty pharmaceuticals• Industry consolidation• Inventory management agreements and discounts• State-funded healthcare, reimbursements and clawbacks• Parallel trade and related issues• Impact of recent regulatory changes• Supermarket pharmacies, chain pharmacies and vertical integration• Pedigree legislation and using the supply chain to combat drug counterfeiting.

Market value for 2014 and prospects for the future

What does the future hold? The pharma industry and its supply chain partners will increase revenues from 2012 to 2022. Overall world revenue for wholesale and distribution activities will reach $747bn in 2014, the report forecasts.

What are companies doing? Our work profiles nine leading W&D organisations and investigates their revenue-generating prospects to 2022:

• McKesson

• Cardinal Health

• AmerisourceBergen

• The PHOENIX Group

• Alfresa Holdings

• Celesio

• Alliance Boots

• Suzuken

• Medipal.

The scope of the field widens, with organisations collaborating and expanding their businesses. Our investigation shows you commercial possibilities.

Increased unit sales of generic drugs will restrain revenue growth, as will direct-to-pharmacy distribution. Demand for specialty pharma products will augment sales, the study also finds.

There will be increasing dependence on emerging countries to 2022, with their fast-rising drug sales. Developed countries hold promise too.

New products - novel small molecules, generics and biologics - will stimulate the pharma sector. Many opportunities for rising drug sales exist, with high, growing W&D revenues possible from 2012 to 2022. Our report shows you and explains.

Forecasts, market shares, developmental trends, commercial news and discussions

In visiongain's study you find revenue forecasting, growth rates and market shares. Also, you see qualitative analyses (SWOT and STEP), company profiles and commercial developments. You receive 62 tables, 41 charts and two research interviews.

Eight ways Pharma Wholesale and Distribution Market: World Outlook 2012-2022 helps you

In particular, our report gives you the following knowledge on the topic:• Find potential revenues to 2022 for the overall world market and submarkets• Discover projected revenue trends to 2022 for nine leading companies• See market forecasting to 2022 for the US, Japan, EU5 countries, Brazil,Russia, China and India• Assess leading companies, and other players, discovering activities and outlooks• Review issues and events in the industry and market - emerging trends• Investigate competition and opportunities influencing unit sales and revenues• Find out what will stimulate and restrain the industry and market• View opinions from the industry, reading interviews from our survey.

There, you discover quantitative and qualitative analyses with independent predictions. You receive information that only our report contains, staying informed on business intelligence.

Without our report you could miss out on information that your competitors use.Gain research and analysis now for the supply of medicines

Our study is for everybody needing industry and market analyses for the supply of pharmaceuticals. You find data, predictions and answers there. Please order that report now.

Table of Contents 1. Executive Summary

1.1 Overview of the Study

1.2 Chapter Breakdown

1.3 Research and Analysis Methods

2. Introduction to the Market2.1 The Role of Pharmaceutical Wholesalers2.1.1 Full-Line Wholesalers (FLWs)2.1.2 Short-Line Wholesalers (SLWs)2.2 The Chain of Distribution2.2.1 Secondary Wholesalers2.2.2 Direct-to-Pharmacy2.2.3 Pharmacy Benefit Managers2.3 Generating Revenue and Profit2.3.1 Forward Buying2.3.2 Fee-for-Service2.3.2.1 Inventory Management Agreements2.3.3 Discounts 2.3.4 Reimbursement and Wholesalers2.3.5 Clawback2.3.6 Parallel Trade

3. The World Pharmaceutical Wholesale and Distribution Market, 2012-2022

3.1 The World Market in 2011

3.2 World Market Forecast, 2012-2022

3.3 Branded and Generic Drugs

3.3.1 Branded and Generic Drugs: Revenue Generation, 2011

3.3.2 Branded and Generic Drugs: Revenue Forecasts, 2012-2022

4. Pharmaceutical Wholesale and Distribution Industry: Leading National Markets, 2012-20224.1 The US4.1.1 An Increase in Fee-for-Service Activity4.1.2 US Market Forecast, 2012-20224.2 Europe4.2.1 Differences between the US and Europe4.2.1.1 State-Funded Healthcare and Reimbursement4.2.2 Europe and Leading EU Countries: Market Forecasts, 2012-2022 4.2.3 Germany4.2.3.1 Healthcare Reform4.2.3.2 Market Forecast, 2012-20224.2.4 France4.2.4.1 Market Forecast, 2012-20224.2.5 Spain4.2.5.1 Market Forecast, 2012-20224.2.6 The UK 4.2.6.1 Price Cuts4.2.6.2 Market Forecast, 2012-2022 4.2.7 Italy4.2.7.1 Market Forecast, 2012-2022 4.3 Japan4.3.1 Drug Pricing and Performance Fees4.3.2 Market Forecast, 2012-2022 4.4 China4.4.1 Leading Companies4.4.2 Recent Market Developments4.4.3 Market Forecast, 2012-2022 4.5 Brazil4.5.1 Leading Companies4.5.2 Market Forecast, 2012-20224.6 Russia4.6.1 Market Trends4.6.2 Market Forecast, 2012-2022 4.7 India4.7.1 Market Forecast, 2012-20224.8 Concluding Comments

5. Leading Pharma Wholesalers and Distributors in 2012

5.1 Revenue vs. Profit

5.1.1 Profit Margins

5.2 Leading Companies: Grouped Forecasts, 2012-2022

5.3 McKesson

5.3.1 Recent Performance

5.3.2 Future Strategies

5.3.3 Revenue Forecast, 2012-2022

5.4 Cardinal Health

5.4.1 Segment Reorganisation

5.4.2 Recent Performance

5.4.3 Future Strategies

5.4.4 Revenue Forecast, 2012-2022

5.5 AmerisourceBergen

5.5.1 Recent Performance

5.5.2 Future Strategies

5.5.3 Revenue Forecast, 2012-2022

5.6 The PHOENIX Group

5.6.1 Recent Performance

5.6.2 The Tamro Group 2011

5.6.3 Future Strategies

5.6.4 Revenue Forecast, 2012-2022

5.7 Alfresa Holdings

5.7.1 Recent Performance

5.7.2 Future Strategies

5.7.3 Revenue Forecast, 2012-2022

5.8 Celesio

5.8.1 Recent Performance

5.8.2 Future Strategies

5.8.3 Revenue Forecast, 2012-2022

5.9 Alliance Boots

5.9.1 Recent Performance

5.9.2 Future Strategies

5.9.3 Revenue Forecast, 2012-2022

5.10 Suzuken

5.10.1 Recent Performance

5.10.2 Future Strategies

5.10.3 Revenue Forecast, 2012-2022

5.11 Medipal

5.11.1 Recent Performance

5.11.2 Future Strategies

5.11.3 Revenue Forecast, 2012-2022

6. Qualitative Industry and Market Analyses, 2012-20226.1 Strengths6.1.1 Large Companies Dominate the Market6.1.2 Wholesalers Do More than Deliver Drugs6.1.2.1 Pre-Wholesaling6.2 Weaknesses6.2.1 Counterfeiting6.2.2 Low Margins6.3 Opportunities6.3.1 Increased Demand for Pharmaceuticals6.3.2 Generics6.3.3 Globalisation6.4 Threats6.4.1 Direct-to-Pharmacy (DTP)6.4.1.1 DTP in Europe6.4.1.2 The UK6.4.1.3 Poland6.4.1.4 DTP in Australia6.4.1.5 Further Expansion6.4.2 Healthcare Budget Cuts6.4.3 Diversion and Re-importation6.4.4 Supermarket Pharmacies6.4.4.1 Case Study: Walmart

7. Pharmaceutical Wholesale Industry Trends in 2012

7.1 Combating Counterfeit Medicines

7.1.1 The US and E-Pedigree

7.1.2 European Pedigree Legislation

7.1.3 Anti-Counterfeiting Strategies in Other Markets

7.1.4 Issues in Serialisation for Wholesalers

7.2 Growth in Specialty Pharmaceuticals

7.3 Industry Consolidation

7.4 Chain Pharmacies and Vertical Integration

7.5 Impact of Recent Regulatory Changes

8. Research Interviews8.1 Interview with Monika Derecque-Pois, Director General, European Association of Pharmaceutical Full-line Wholesalers (GIRP)8.1.1 Key Unmet Needs8.1.2 Impact of Recent Regulatory Changes8.1.3 Value-Added Services8.1.4 Use of Novel Technologies8.2 Interview with Geoff Mellor and Martin Sawer, British Association of Pharmaceutical Wholesalers (BAPW)8.2.1 Recent Regulatory Changes8.2.2 Use of Technology8.2.3 Fast-Growing Sectors?

9. Conclusions from the Study

9.1 There Will Be Steady Growth in Developed National Markets

9.1.1 Generics Will Threaten Revenues

9.1.2 Manufacturers Will Deliver More Drugs Directly

9.1.3 There Will Be Greater Demand for Specialty Medicines

9.2 Growth Will Be Fastest in Emerging National Markets

9.2.1 Consolidation Will Drive Growth

9.3 Anti-Counterfeiting Demands Will Add to Wholesalers' Costs

9.4 Concluding Remarks

List of Tables Table 2.1 Prevalence of the DTP Model in the UK, 2012

Table 3.1 World Pharmaceutical W&D Market Forecast ($bn), 2011-2022

Table 3.2 World Pharmaceutical W&D Market: Drivers and Restraints, 2012-2022

Table 3.3 Branded and Generic Drugs: Revenue Forecasts ($bn), 2011-2022

Table 3.4 Main Patent Expiries, 2011-2014

Table 3.5 Branded Drugs: Revenue Forecast ($bn), 2011-2022

Table 3.6 Generic Drugs; Revenue Forecast ($bn), 2011-2022

Table 3.7 Percent Revenue Generation Forecast: Branded vs. Generics, 2011-2022

Table 4.1 Pharmaceutical Wholesale and Distribution Market: Sales ($bn) and Market Shares (%) by Country, 2011

Table 4.2 Pharmaceutical Wholesale and Distribution Market: Leading National Revenue Forecasts ($bn), 2011-2022

Table 4.3 US Market: Revenues ($bn) and Market Shares (%) by Company, 2011

Table 4.4 The US Pharmaceutical W&D Market Forecast ($bn), 2011-2022

Table 4.5 US Market Drivers and Restraints, 2012-2022

Table 4.6 EU5 Pharmaceutical W&D Market by Country: Sales ($bn) and Market Shares (%), 2011

Table 4.7 Prominent Price Controls in Europe, 2012

Table 4.8 EU5 Pharmaceutical W&D Market: Forecasts ($bn), 2012-2022

Table 4.9 EU5 Market Drivers and Restraints, 2012-2022

Table 4.10 German Pharmaceutical W&D Market Forecast ($bn), 2011-2022

Table 4.11 German Market Drivers and Restraints, 2012-2022

Table 4.12 French Pharmaceutical W&D Market Forecast ($bn), 2011-2022

Table 4.13 French Market Drivers and Restraints, 2012-2022

Table 4.14 Spanish Pharmaceutical W&D Market Forecast ($bn), 2012-2022

Table 4.15 Spanish Market Drivers and Restraints, 2012-2022

Table 4.16 UK Pharmaceutical W&D Market Forecast ($bn), 2012-2022

Table 4.17 UK Market Drivers and Restraints, 2012-2022

Table 4.18 Italian Pharmaceutical W&D Market Forecast ($bn), 2011-2022

Table 4.19 Italian Market Drivers and Restraints, 2012-2022

Table 4.20 Proportions (%) of Population Aged Over 65 Years by Region, 2025 and 2050

Table 4.21 Japanese Pharmaceutical W&D Market Forecast ($bn), 2011-2022

Table 4.22 Japanese Market Drivers and Restraints, 2012-2022

Table 4.23 Chinese Pharmaceutical W&D Market Forecast ($bn), 2011-2022

Table 4.24 Chinese Market Drivers and Restraints, 2012-2022

Table 4.25 Brazilian Pharmaceutical W&D Market Forecast ($bn), 2011-2022

Table 4.26 Brazilian Market Drivers and Restraints, 2012-2022

Table 4.27 Russian Pharmaceutical W&D Market Forecast ($bn), 2011-2022

Table 4.28 Russian Market Drivers and Restraints, 2012-2022

Table 4.29 Indian Pharmaceutical W&D Market Forecast ($bn), 2011-2022

Table 4.30 Indian Market Drivers and Restraints, 2012-2022

Table 5.1 Leading W&D Companies: Revenues ($bn) and Market Shares (%), 2011

Table 5.2 Leading W&D Companies: Revenue Forecasts ($bn), 2011-2022

Table 5.3 W&D Market Leaders: Commercial Drivers and Restraints, 2012-2022

Table 5.4 McKesson Pharmaceutical Wholesale Revenue by Country ($bn), 2011

Table 5.5 McKesson Pharmaceutical Gross Profit Margin (%), 2009-2011

Table 5.6 McKesson Revenue Forecast ($bn), 2011-2022

Table 5.7 Cardinal Health Revenue Forecast ($bn), 2011-2022

Table 5.8 AmerisourceBergen Revenue Forecast ($bn), 2011-2022

Table 5.9 The PHOENIX Group: Wholesale Subsidiaries, 2010

Table 5.10 The Tamro Group, 2011

Table 5.11 The PHOENIX Group Revenue Forecast ($bn), 2011-2022

Table 5.12 Alfresa Wholesale Subsidiaries , 2011

Table 5.13 Alfresa Holdings Revenue Forecast ($bn), 2011-2022

Table 5.14 Celesio Wholesale Subsidiaries, 2010

Table 5.15 Celesio Wholesale Revenue ($bn) by Country, 2011

Table 5.16 Celesio Revenue Forecast ($bn), 2011-2022

Table 5.17 Alliance Boots Wholesale Revenue ($bn) by Country, 2011

Table 5.18 Alliance Boots Revenue Forecast ($bn), 2011-2022

Table 5.19 Suzuken Revenue Forecast ($bn), 2011-2022

Table 5.20 Medipal Revenue Forecast ($bn), 2011-2022

Table 6.1 SWOT Analysis of the World W&D Industry and Market, 2012-2022

Table 6.2 STEP Analysis of the World W&D Industry and Market, 2012-2022

Table 6.3 Strengths and Weaknesses of the DTP Model, 2012

Table 9.1 Overall Pharmaceutical Wholesale Revenue ($bn) and Market Shares (%) by Leading Country, 2011, 2015 & 2022

List of Figures Figure 2.1 Traditional Routes of Drug Distribution, 2012

Figure 3.1 World Pharmaceutical W&D Market Forecast ($bn), 2011-2022

Figure 3.2 Branded Drugs: Revenue Forecast ($bn), 2011-2022

Figure 3.3 Generic Drugs: Revenue Forecast ($bn), 2011-2022

Figure 3.4 Percent Revenue Generation Forecast: Branded vs. Generics, 2011-2022

Figure 4.1 World Pharmaceutical Wholesale and Distribution Market Shares (%) by Country, 2011

Figure 4.2 World Pharmaceutical Wholesale and Distribution Market Shares (%) by Country, 2015

Figure 4.3 World Pharmaceutical Wholesale and Distribution Market Shares (%) by Country, 2022

Figure 4.4 US Market Shares (%) by Leading Company, 2011

Figure 4.5 US Pharmaceutical W&D Market Forecast ($bn), 2011-2022

Figure 4.6 EU5 Pharmaceutical Wholesale and Distribution Market Shares (%) by Country, 2011

Figure 4.7 European W&D Market: Overall Revenue Forecast ($bn), 2011-2022

Figure 4.8 German Pharmaceutical W&D Market Forecast ($bn), 2011-2022

Figure 4.9 French Pharmaceutical W&D Market Forecast ($bn), 2011-2022

Figure 4.10 Spanish Pharmaceutical W&D Market Forecast ($bn), 2012-2022

Figure 4.11 UK Pharmaceutical W&D Market Forecast ($bn), 2012-2022

Figure 4.12 Italian Pharmaceutical W&D Market Forecast ($bn), 2011-2022

Figure 4.13 Population Proportions (%) Aged Over 65 by Region, 2025 and 2050

Figure 4.14 Japanese Pharmaceutical W&D Market Forecast ($bn), 2011-2022

Figure 4.15 Chinese Pharmaceutical W&D Market Forecast ($bn), 2011-2022

Figure 4.16 Brazilian Pharmaceutical W&D Market Forecast ($bn), 2011-2022

Figure 4.17 Russian Pharmaceutical W&D Market Forecast ($bn), 2011-2022

Figure 4.18 Indian Pharmaceutical W&D Market Forecast ($bn), 2011-2022

Figure 5.1 Leading W&D Companies: Market Shares (%), 2011

Figure 5.2 McKesson Pharmaceutical Wholesale Revenue (%) by Country, 2011

Figure 5.3 McKesson Pharmaceutical Gross Profit Margin (%), 2009-2011

Figure 5.4 McKesson Revenue Forecast ($bn), 2011-2022

Figure 5.5 Cardinal Health Revenue (%) by Company, 2011

Figure 5.6 Cardinal Health Revenue Forecast ($bn), 2011-2022

Figure 5.7 AmerisourceBergen Revenue Forecast ($bn), 2011-2022

Figure 5.8 The Tamro Group: Revenue Shares (%) by Country, 2011

Figure 5.9 The PHOENIX Group Revenue Forecast ($bn), 2011-2022

Figure 5.10 Alfresa Holdings Revenue Forecast ($bn), 2011-2022

Figure 5.11 Celesio Wholesale Revenue Shares (%) by Country, 2011

Figure 5.12 Celesio Revenue Forecast ($bn), 2011-2022

Figure 5.13 Alliance Boots Wholesale Revenues ($bn) by Country, 2011

Figure 5.14 Alliance Boots Revenue Forecast ($bn), 2011-2022

Figure 5.15 Suzuken Revenue Forecast ($bn), 2011-2022

Figure 5.16 Medipal Revenue Forecast ($bn), 2011-2022

Figure 6.1 Comparison of the Wholesaler and Direct-to-Pharmacy Routes, 2012

Figure 7.1 Anti-Counterfeiting Strategies in the US and Europe, 2012

Companies Listed AAH Pharmaceuticals

AB Acquisitions Ltd

Acofarma (Asociación Cooperativas Farmacéuticas)

Admenta Italia

Alfresa Holdings Corp

Alfresa Medical Service Corp

Alfresa Nikken Sangyo

Alliance Boots

Alliance Healthcare

Alliance Santé

Alliance UniChem

Amedis-UE AG

AmerisourceBergen

Anderson Packaging

Ando Co.

Andreae-Noris Zahn (ANZAG)

Apokjeden

Australian Pharmaceutical Industries

Astellas Pharma

Astis Co

AstraZeneca

Athos Farma

Atol Co

Bayer

Bergen Brunswig

Brecon Pharmaceuticals

Bristol-Myers Squibb

British Association of Pharmaceutical Wholesalers (BAPW)

Brocacef Holding

Bundesverband des Pharmazeutischen Grosshandel

Cahill May Roberts

Cardinal Health

CareFusion

Celesio

Center for Medicine in the Public Interest

CERP network

Chambre Syndicale de la Répartition Pharmaceutique (CSRP)

China National Pharmaceutical Group (Sinopharm)

Chiyaku Co

Cipla

Cofares

Comifar Group

CS Yakuhin Co

CVS Caremark

Eli Lilly

European Association of Euro-Pharmaceutical Companies (EAEPC)

European Association of Pharmaceutical Full-line Wholesalers (GIRP)

European Federation of Pharmaceutical Industries and Associations (EFPIA)

Everlth Co.

Food and Drug Administration (US FDA)

Fukujin Co.

Galenica

GEHE Pharma Praha

GSK

Guangzhou Pharmaceuticals Corporation (GP Corp)

Healthcare Distribution Management Association (HDMA)

Hedef Alliance Holding

Hefame

Heisei Yakuhin Co.

Herba Chemosan

Hubei Kyoso Pharmaceutical

Humana

Huzhong Pharmaceutical Co.

HydraPharm

Inten

Izutsu Pharmaceutical Co.

Japanese Pharmaceutical Wholesalers Association

Jingu Yakuhin Co.

Jointown Pharmaceutical Group

Katren

Kemofarmacija

Kinray

Kobashou Co. (Kobayashi Group Company)

Kohlberg Kravis Roberts & Co.

Kowa Pharmaceuticals Co.

Kuraya Sanseido

Laboratoria Flandria

Libra

McKesson

Medco Health Solutions

Medicaid

MEDICEO CORPORATION

Medicine Shoppe International

MediPal

Meisho Co.

Merck & Co.

Mitsubishi

Miyagi Distribution Center

Nadro

Nakagawa Seikodo Co

Nakano Yakuhin Co

Napp Pharmaceutical

National Health Service (NHS UK)

Nomeco

Norsk Medisinaldepot

Novo Nordisk

OCP

Odashima

Oncology Therapeutics Network

Oncoprod

Panpharma

Parata Systems

Pfizer

Pharma Belgium

Pharmaceutical Security Institute (PSI)

PHOENIX Arzeiwarengro?handlung

PHOENIX Farmacija

PHOENIX Lékárensky

PHOENIX Medical Supplies

PHOENIX Pharma

PHOENIX Pharma Polska

PHOENIX Pharmahandel

PHOENIX Zdravotócke

Polska Grupa Farmaceutyczna

Profarma

Prosper

Protek

Ratiopharm

Rite Aid Pharmacy

Roche

Rosta

Ryuyaku Co

Sanacorp

Sanki Corporation

Sanofi

Seiwa Sangyo Co

Shanghai Pharmaceutical Co

Shikoku Alfresa Corp

Shoyaku Co

SIA International

Sigma Pharmaceuticals

Sincamesp

Sinopharm

State Food and Drug Administration (SFDA, China)

Suzuken

Suzuken Iwate Co

Suzuken Okinawa Yakuhin Co

Target

Teva

Institute for Pharmaeconomic Research (IPF)

The PHOENIX Group

The Tamro Group

Tjellesen Max Jenne

Toho Holdings

Torfarm

UniChem

US Oncology

Ushioda Sagokudo Yakuhin Co

Vitapharm

Walgreens Co.

Walmart

World Courier Group

Wyeth Pharmaceuticals (now part of Pfizer)

ZAO Rosta

Zuellig Pharma China (Yong Yu)

To order this report:Pharmaceutical Industry: Pharma Wholesale and Distribution Market: World Outlook 2012-2022

More  Market Research Report

Check our  Industry Analysis and Insights

Nicolas Bombourg

Reportlinker

Email: nicolasbombourg@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626

 


'/>"/>
SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved


Related medicine technology :

1. PAREXEL Strengthens Outcomes Research Capabilities To Help Biopharma Meet Commercialization Goals
2. Onyx Pharmaceuticals Reports Second Quarter 2012 Financial Results
3. Save Up To 25% on International Biotech and Healthcare, and Pharmaceutical Conferences by Registering Through GII
4. Genelex Receives First Patent on Business Methods for Pharmacogenetics
5. Qforma Chief Technologist Honored as One of PharmaVOICE Magazines "100 Most Inspiring People in the Life Sciences"
6. MAP Pharmaceuticals, Inc. Prices Public Offering of Common Stock
7. Avanir Pharmaceuticals Announces Date Of Fiscal 2012 Third Quarter Financial Results And Conference Call
8. AcelRx Pharmaceuticals Receives Two Additional U.S. Patents for Small-Volume Oral Transmucosal Dosage Forms
9. Actinium Pharmaceuticals Announces The Addition of The Fred Hutchinson Cancer Research Center To Actiniums Multicenter Clinical Trial For Patients With Acute Myeloid Leukemia
10. CPhI China 2012 Breaks Attendance Records in Growing Pharma Market
11. Synergy Pharmaceuticals to Present Scientific Posters at the Upcoming Gastroenterology Society Meetings in the U.S. and Europe
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... 2016 The global  gamma ... billion by 2022, according to a new report ... towards a healthy lifestyle is expected to drive ...      (Logo: http://photos.prnewswire.com/prnh/20150105/723757 ) , ... health treatment expenditure has urged consumers to switch ...
(Date:4/26/2016)... FLINT, Mich. , April 26, 2016 ... the promotion of Jennifer Hagerman , Pharm D., ... In her growing role at Diplomat, Hagerman will continue ... of the company that delivers custom education and training ... to the specialty pharmacy industry. Diplomat University also houses ...
(Date:4/26/2016)... 26, 2016 US demand for infection ... 4.9 percent annually to $27.6 billion in 2020.  ... to decrease rates of healthcare-associated infections (HAIs) will ... and services.  Although declining, the overall rate of ... levels set by the CDC.  Recent statistics indicate ...
Breaking Medicine Technology:
(Date:4/30/2016)... ... April 30, 2016 , ... Orlando-based Maximized Living has selected Dr. Nick ... in Rio. Under the care of Maximized Living doctors at the London Olympics ... showing, Maximized Living is sending the largest contingent of elite chiropractors to Rio to ...
(Date:4/29/2016)... Ferry, New York (PRWEB) , ... April 30, 2016 , ... ... the Dobbs Ferry campus. The following programs will be expanding due to high ... Management (HRM). The expansion will begin this summer. , School of ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... Foundation, the national charitable foundation serving the footwear industry, has broken all previous ... more than 130 companies across 23 states during the months of April and ...
(Date:4/29/2016)... ... 2016 , ... Shamangelic Healing, Sedona Arizona's Premier Center ... BRAIN and New Mood Daily-Stress Formula for brain optimization and wellness to their ... store is just one more way Shamangelic Healing supports people’s quest for health, ...
(Date:4/29/2016)... ... April 29, 2016 , ... On Tuesday, April 26, 2016 ... Southeast, celebrated the signature of Gov. Nathan Deal on SB 258, the “Rural Health ... - Cumming), offers a 70% tax credit to individuals and corporations which donate directly ...
Breaking Medicine News(10 mins):